MyFinsight
Home
Blog
About
Contact
Download
Download image
Net increase in cash
and cash...
$11,133K
Proceeds from issuance of
october 2025 pre-funded...
$5,946K
Net proceeds from
issuance of preferred...
$3,786K
Net proceeds from
issuance of preferred...
$2,049K
Proceeds from warrants
exercise-Warrants And Prefunded...
$852K
Net decrease in
cash, cash...
$7,318K
Canceled cashflow
$3,815K
Net cash provided by
financing activities,...
$4,615K
Canceled cashflow
$8,018K
Net decrease in
cash, cash...
-$3,815K
Canceled cashflow
$4,615K
Non-cash loss (gain) on
changes in fair value of...
$24,486K
Impairment of long-lived
assets
$854K
Amortization of debt
discounts on convertible...
$248K
Non-cash right-of-use
amortization
$140K
Stock-based compensation
expense related to...
$29K
Dividend paid
$4,817K
Payments on warrants
purchase
$2,001K
Cash payment
pursuant to warrant...
$525K
Payment on bridge note
$500K
Payment on redemption of
series f preferred...
$175K
Net cash used in
operating activities,...
-$8,430K
Canceled cashflow
$25,757K
Net loss
-$22,141K
Net income from
discontinued operations, net...
-$11,081K
Prepaid expenses and
other current assets
$445K
Operating lease
liabilities
-$398K
Other assets
$85K
Accounts payable and
accrued liabilities
-$37K
Back
Back
Cash Flow
source: myfinsight.com
NovaBay Pharmaceuticals, Inc. (NBY)
NovaBay Pharmaceuticals, Inc. (NBY)